SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders

Luciana Teofili, Livio Pagano, Marianna Criscuolo, Caterina Giovanna Valentini, Roberta Di Blasi, Alessandro Busca, Simone Cesaro, Mario Delia, Chiara Cattaneo, Francesco Marchesi, Nicola Stefano Fracchiolla, Francesca Farina, Lucia Prezioso, Angelica Spolzino, Anna Candoni, Maria Ilaria Del Principe, Luisa Verga, Annamaria Nosari, Franco Aversa

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

The rapid spread of severe infections mainly due to resistant pathogens, justifies the search for therapies aiming to restore immune functions severely compromised in patients with hematologic malignancies. Areas covered: The present review summarizes the current knowledge on the role of granulocyte transfusions and colony-stimulating factors as treatment strategy for hematologic patients with serious infectious complications. In addition, a survey among 21 hematologic centers, to evaluate the clinical practice for the use of G-CSF originator and biosimilars was performed. Expert commentary: Granulocyte transfusions with a target dose of at least 1.5-3 × 108 cells/kg, may be considered as an approach to bridge the gap between marrow suppression and recovery of granulocytes. G-CSF shortens the period of neutropenia, the hospitalization, the use of antibiotics and the rate of febrile neutropenia (FN) in adult and pediatric patients with non-Hodgkin lymphoma, and in adults with acute myeloid leukemia where these advantages nevertheless, did not translate into a clinical benefit. G-CSF biosimilar showed equivalence or non-inferiority to filgrastim. There are no data supporting the use of GM-CSF, eltrombopag and erythropoietin for preventing or treating infectious complications in patients with hematologic disorders.
Lingua originaleEnglish
pagine (da-a)1-14
Numero di pagine14
RivistaExpert Review of Hematology
DOI
Stato di pubblicazionePubblicato - 2018

Keywords

  • Hematologic malignancies
  • colony-stimulating factors
  • granulocyte transfusions
  • infectious complications
  • invasive fungal infections

Fingerprint Entra nei temi di ricerca di 'SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders'. Insieme formano una fingerprint unica.

Cita questo